PILOTforPulmonary.org: COVID-19 and Monoclonal Antibodies
Designed for pulmonologists, infectious disease specialists, primary care physicians, nurse practitioners, PAs, and other health care providers who treat patients with COVID-19 and want to enhance their knowledge of monoclonal antibodies, this highly interactive learning activity features animations, faculty videos, downloadable resources, and more.
Cost: FreeView Offer chevron_right
The France Foundation’s new EXPLORE™ modules put learners in the driver seat, allowing them to navigate content on their own time and driven by their own interests. This approach reduces virtual fatigue, ensures increased engagement and activity completions.
COVID-19, monoclonal antibody therapy, immunosuppresed patients, at-risk patients, safey and efficacy of emerging monoclonal antibody therapy, combination therapy, viral load, infusion centers
- Review the utility of administering monoclonal antibodies for the management of at-risk patients with COVID-19, including variants
- Explain how management of COVID-19 with monoclonal antibodies affects viral load
- Recognize specific IDSA and NIH guideline-recommended treatments for at-risk patients and select appropriate monoclonal antibody therapy for patients with COVID-19, including combination therapy
- Describe the use of monoclonal antibodies in immunosuppressed patients with COVID-19
- Discuss the safety and efficacy of the available and emerging monoclonal antibodies for the management of at-risk patients with COVID-19
This activity is intended for pulmonologists, infectious disease specialists, primary care providers, and other health care providers who may be involved in the management of patients with COVID-19.
Additional credit info
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.